NovaBay Pharmaceuticals, Inc. (NBY)
Market Cap | 2.35M |
Revenue (ttm) | 14.23M |
Net Income (ttm) | -18.55M |
Shares Out | 1.08M |
EPS (ttm) | -121.80 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 18,108 |
Open | 2.230 |
Previous Close | 2.240 |
Day's Range | 2.150 - 2.270 |
52-Week Range | 2.050 - 44.800 |
Beta | 1.90 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 8, 2024 |
About NBY
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care ... [Read more]
Financial Performance
In 2023, NBY's revenue was $14.73 million, an increase of 2.24% compared to the previous year's $14.40 million. Losses were -$16.70 million, 2.66% more than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/h/f/press2-2504821.jpg)
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ:...
![](https://cdn.snapi.dev/images/v1/v/p/press10-2501486.jpg)
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to custo...
![](https://cdn.snapi.dev/images/v1/w/g/press5-2467863.jpg)
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company's plan to regai...
![](https://cdn.snapi.dev/images/v1/d/z/press11-2452720.jpg)
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company's Definitive Proxy Sta...
![](https://cdn.snapi.dev/images/v1/l/b/press17-2426925.jpg)
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduct...
![](https://cdn.snapi.dev/images/v1/w/s/press3-2422604.jpg)
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. “Net produc...
![](https://cdn.snapi.dev/images/v1/7/m/press3-2414454.jpg)
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordere...
![](https://cdn.snapi.dev/images/v1/b/2/conf18-2408680.jpg)
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on...
![](https://cdn.snapi.dev/images/v1/s/p/press3-2382654.jpg)
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enh...
![](https://cdn.snapi.dev/images/v1/p/e/press12-2381533.jpg)
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is be...
![](https://cdn.snapi.dev/images/v1/x/7/press15-2375362.jpg)
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 m...
![](https://cdn.snapi.dev/images/v1/p/e/press12-2342752.jpg)
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update. “...
![](https://cdn.snapi.dev/images/v1/z/l/conf5-2340856.jpg)
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after marke...
![](https://cdn.snapi.dev/images/v1/t/v/press4-2324119.jpg)
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Comp...
![](https://cdn.snapi.dev/images/v1/a/d/press20-2250827.jpg)
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and ...
![](https://cdn.snapi.dev/images/v1/h/h/press18-2222356.jpg)
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network
EMERYVILLE, Calif. & BOULDER, Colo.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and m...
![](https://cdn.snapi.dev/images/v1/h/x/press3-2185189.jpg)
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of am...
![](https://cdn.snapi.dev/images/v1/f/a/press10-2150920.jpg)
NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update...
![](https://cdn.snapi.dev/images/v1/b/y/conf16-2135459.jpg)
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after ma...
![](https://cdn.snapi.dev/images/v1/v/j/press20-2098504.jpg)
NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the...
![](https://cdn.snapi.dev/images/v1/j/j/conf3-2085373.jpg)
NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that...
![](https://cdn.snapi.dev/images/v1/r/i/press12-2063332.jpg)
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U...
![](https://cdn.snapi.dev/images/v1/d/i/press12-2057340.jpg)
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has b...
![](https://cdn.snapi.dev/images/v1/t/i/press10-2018421.jpg)
NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2023 and provides a business update. “Net...
![](https://cdn.snapi.dev/images/v1/b/3/conf17-2013059.jpg)
NovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2023 after market c...